Icahn wants all of Mylan ...

Mylan (MYL) today got an offer of $20/share for all its shares from Carl Icahn. I hope it doesn't go through - Mylan is worth much more after the recent generics M & A activity. The market doesn't seem to believe that this is a worthwhile offer either - Mylan is trading at only $19/share!

Meanwhile, 3 other generics look very attractive now -

• Ivax (IVX) : a takeover target - cheap after the recent warning.
  
• Andrx (ADRX) : another target - somewhat cheap.
  
• Teva (TEVA) : one of the biggies. Not a target, but a value play.